Enliven CMO nets 5,000-share stock sale, option exercise

Enliven Therapeutics, Inc. chief medical officer Helen Louise Collins reported a mix of option exercise and share sales in the company’s stock.

Filing Impact

(Neutral)

Filing Sentiment

(Neutral)How Sentiment works

Sentiment and the balance of points

Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.

How Sentiment works How the balance works

Form Type

Rhea-AI Filing Summary

Enliven Therapeutics, Inc. chief medical officer Helen Louise Collins reported a mix of option exercise and share sales in the company’s stock. On June 17, 2026, she exercised options for 5,000 shares of common stock at a strike price of $2.48 per share, then sold a total of 5,000 shares in three open-market transactions at weighted average prices of $42.8270, $43.8701 and $44.7430 per share. These trades were made under a pre-arranged Rule 10b5-1 trading plan adopted on October 19, 2025. Following the transactions, she holds 25,000 shares of common stock directly and 121,268 stock options.

Insider Trade Summary 10b5-1

Exercise and Sale: 5,000 shares ($207K approx. pre-tax spread)

Exercise and Sale 5 txns

Insider Collins Helen Louise

Role CHIEF MEDICAL OFFICER

Sold 5,000 shs ($219K)

Approx. gross sale proceeds $219K

Approx. exercise cost $12K

Approx. pre-tax spread $207K

Type	Security	Shares	Price	Value
Exercise	Stock Option (right to buy)	5,000	$0.00	$0.00
Exercise	Common Stock	5,000	$2.48	$12K
Sale	Common Stock	1,268	$42.827	$54K
Sale	Common Stock	2,599	$43.8701	$114K
Sale	Common Stock	1,133	$44.743	$51K

Holdings After Transaction: Stock Option (right to buy) — 121,268 contracts (Direct); Common Stock — 25,000 shares (Direct)

Footnotes (7)

F1. The option exercise and sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on October 19, 2025.
F2. Certain of these securities are restricted stock units (RSUs). Each RSU represents a contingent right to receive one share of the Issuer's Common Stock.
F3. This transaction was executed in multiple trades at prices ranging from $42.295 to $43.2752. The price reported above reflects the weighted average sale price. The Reporting Person undertakes to provide upon request by the staff of the Securities and Exchange Commission, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate sale price.
F4. This transaction was executed in multiple trades at prices ranging from $43.30 to $44.2925. The price reported above reflects the weighted average sale price. The Reporting Person undertakes to provide upon request by the staff of the Securities and Exchange Commission, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate sale price.
F5. This transaction was executed in multiple trades at prices ranging from $44.3005 to $44.95. The price reported above reflects the weighted average sale price. The Reporting Person undertakes to provide upon request by the staff of the Securities and Exchange Commission, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate sale price.
F6. These securities are RSUs. Each RSU represents a contingent right to receive one share of the Issuer's Common Stock.
F7. All of the shares subject to this option are fully vested and exercisable as of the date hereof.

Key Figures

Shares sold: 5,000 shares Sale prices: $42.8270, $43.8701, $44.7430 per share Options exercised: 5,000 options +3 more

6 metrics

Shares sold 5,000 shares Total common stock sold June 17, 2026

Sale prices $42.8270, $43.8701, $44.7430 per share Weighted average prices for three open-market sales

Options exercised 5,000 options Stock option exercise on June 17, 2026

Option strike price $2.48 per share Exercise price for 5,000 stock options

Shares held after 30,000 shares Common stock directly owned following transactions

Options held after 121,268 options Stock options outstanding and fully vested after exercise

Key Terms

Rule 10b5-1 trading plan, restricted stock units (RSUs), weighted average sale price, Stock Option (right to buy)

4 terms

Rule 10b5-1 trading plan regulatory

"were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person"

A Rule 10b5-1 trading plan is a pre-arranged schedule that allows company insiders to buy or sell stock at specific times, even if they have inside information. It helps prevent accusations of unfair trading by making these transactions look planned and transparent, rather than sneaky or illegal.

restricted stock units (RSUs) financial

"Certain of these securities are restricted stock units (RSUs). Each RSU represents a contingent right"

Restricted stock units (RSUs) are a type of company promise to give employees shares of stock in the future, usually after certain conditions like working for a set time. They are like a gift promised today that you receive later, which can become valuable if the company's stock price goes up. RSUs matter because they are a way companies reward employees and can be a significant part of compensation.

weighted average sale price financial

"The price reported above reflects the weighted average sale price."

Stock Option (right to buy) financial

"security_title": "Stock Option (right to buy)""

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What insider transactions did ELVN’s chief medical officer report?

Helen Louise Collins reported exercising 5,000 stock options at $2.48 and selling 5,000 Enliven Therapeutics common shares in three open-market trades at weighted average prices between $42.8270 and $44.7430, all on June 17, 2026, under a Rule 10b5-1 plan.

How many Enliven Therapeutics (ELVN) shares did the CMO sell?

Helen Louise Collins sold 5,000 shares of Enliven Therapeutics common stock. The sales occurred in three open-market transactions on June 17, 2026, at weighted average prices of $42.8270, $43.8701 and $44.7430 per share, as disclosed in the Form 4 filing.

At what price were the ELVN stock options exercised by the CMO?

The reported stock options were exercised at a strike price of $2.48 per share. This exercise covered 5,000 options, converting them into 5,000 shares of Enliven Therapeutics common stock before the subsequent open-market sales on June 17, 2026.

Were the ELVN insider trades made under a 10b5-1 trading plan?

Yes. The Form 4 states the option exercise and related sales were effected under a Rule 10b5-1 trading plan adopted by Helen Louise Collins on October 19, 2025, indicating the trades were pre-arranged rather than timed discretionarily.

How many Enliven Therapeutics shares does the CMO hold after these trades?

After the reported transactions, Helen Louise Collins holds 30,000 shares of Enliven Therapeutics common stock directly. She also holds 121,268 stock options, all of which are reported as fully vested and exercisable as of the transaction date.

What are RSUs mentioned in the Enliven Therapeutics Form 4 footnotes?

The filing notes that certain securities are restricted stock units, or RSUs. Each RSU represents a contingent right to receive one share of Enliven Therapeutics common stock, meaning the actual shares are delivered only when vesting or other specified conditions are satisfied.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 4 Insider Transactions: What Each Field Means →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google

Accepted by SEC EDGAR 06/22/2026 - 05:11 PM EDT

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Collins Helen Louise

(Last)

(First)

(Middle)

C/O ENLIVEN THERAPEUTICS, INC.

205 PARK ROAD

(Street)

BURLINGAME

CALIFORNIA

94010

(City)

(State)

(Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
Enliven Therapeutics, Inc. [ ELVN ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director	10% Owner
X	Officer (give title below)	Other (specify below)
	CHIEF MEDICAL OFFICER

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
06/17/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	Code	V	Amount	(A) or (D)	Price		6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
Common Stock	06/17/2026		M⁽¹⁾		5,000	A	$2.48	30,000⁽²⁾	D
Common Stock	06/17/2026		S⁽¹⁾		1,268	D	$42.827⁽³⁾	28,732⁽²⁾	D
Common Stock	06/17/2026		S⁽¹⁾		2,599	D	$43.8701⁽⁴⁾	26,133⁽²⁾	D
Common Stock	06/17/2026		S⁽¹⁾		1,133	D	$44.743⁽⁵⁾	25,000⁽⁶⁾	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares	8. Price of Derivative Security (Instr. 5)		10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
Stock Option (right to buy)	$2.48	06/17/2026		M⁽¹⁾			5,000	⁽⁷⁾	06/17/2031	Common Stock	5,000	$0	121,268	D

Explanation of Responses:

1. The option exercise and sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on October 19, 2025.

2. Certain of these securities are restricted stock units (RSUs). Each RSU represents a contingent right to receive one share of the Issuer's Common Stock.

3. This transaction was executed in multiple trades at prices ranging from $42.295 to $43.2752. The price reported above reflects the weighted average sale price. The Reporting Person undertakes to provide upon request by the staff of the Securities and Exchange Commission, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate sale price.

4. This transaction was executed in multiple trades at prices ranging from $43.30 to $44.2925. The price reported above reflects the weighted average sale price. The Reporting Person undertakes to provide upon request by the staff of the Securities and Exchange Commission, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate sale price.

5. This transaction was executed in multiple trades at prices ranging from $44.3005 to $44.95. The price reported above reflects the weighted average sale price. The Reporting Person undertakes to provide upon request by the staff of the Securities and Exchange Commission, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate sale price.

6. These securities are RSUs. Each RSU represents a contingent right to receive one share of the Issuer's Common Stock.

7. All of the shares subject to this option are fully vested and exercisable as of the date hereof.

	/s/ Ben Hohl, by power of attorney	06/22/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)

Source: View Original Filing on SEC EDGAR